[go: up one dir, main page]

NO965160L - New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds - Google Patents

New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds

Info

Publication number
NO965160L
NO965160L NO965160A NO965160A NO965160L NO 965160 L NO965160 L NO 965160L NO 965160 A NO965160 A NO 965160A NO 965160 A NO965160 A NO 965160A NO 965160 L NO965160 L NO 965160L
Authority
NO
Norway
Prior art keywords
residue
optionally substituted
alkyl
transferase inhibitors
farnesyl transferase
Prior art date
Application number
NO965160A
Other languages
Norwegian (no)
Other versions
NO965160D0 (en
Inventor
Bernard Baudoin
Christopher Burns
Alain Commercon
Jean-Dominique Guitton
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9407116A external-priority patent/FR2721021B1/en
Priority claimed from FR9412338A external-priority patent/FR2725717B1/en
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO965160L publication Critical patent/NO965160L/en
Publication of NO965160D0 publication Critical patent/NO965160D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nye farnesyl-transferase-inhibitorer med den generelle formel (I): (I) der RI betyr Y-S-A^- (Y - hydrogenatom, aminosyrerest, fettsyre- rest, alkyl- eller alkoksykarbonylrest eller R4~S, der R4 betyr en C...-alkylrest, som eventuelt er substituert med en fenylrest eller en rest med den generelle formel (II): der A}, Xj, Yj, R'i, fy* ^'2 °6 ^ er som angitt nedenfor, og A^ = C1_.-alkylen, eventuelt substituert i o-poslsjon av gruppen di) med en aminorest eller alkylamino, dialkylamino, alkanoylamlno eller alkoksykarbonylamlno), xl °& ^1 hver betyr et hydrogenatom eller sammen med karbonatomet hvortil de er bundet, danner en gruppe >C=0, R'l betyr hydrogen eller metyl, R2 betyr C..-alkyl, -alkenyl eller -alkynyl som eventuelt er ¿ substituert med hydroksy, alkoksy, merkapto, alkyltio, alkylsulflnyl eller alkylsulfonyl, idet, når R2 betyr en hydroksysubstltuert alkylrest, kan R£ sammen med karboksyresten i o-posisjon danne et lakton, ; R'g betyr hydrogen eller metyl og . R betyr et hydrogenatom eller en eventuelt substituert alkylrest, eller en R, eventuelt substituert fenylrest, idet resten x,¿/^N' er i 5- eller 6-posisjon av naftylkjernen. De nye forbindelser oppviser Interessante farmakologiske egenskaper, således også antlcancerøse egenskaper.Novel farnesyl transferase inhibitors of the general formula (I): (I) wherein R 1 represents YSA 2 - (Y - hydrogen atom, amino acid residue, fatty acid residue, alkyl or alkoxycarbonyl residue or R 4 ~ S, where R 4 represents a C. -alkyl residue optionally substituted with a phenyl residue or a residue of the general formula (II): wherein A}, Xj, Yj, R'i, fy = C1-6 alkylene, optionally substituted in the o-position of the group di) with an amino residue or alkylamino, dialkylamino, alkanoylamino or alkoxycarbonylamino), xl > C = O, R1 represents hydrogen or methyl, R2 represents C1-6 alkyl, -alkenyl or -alkynyl optionally substituted with hydroxy, alkoxy, mercapto, alkylthio, alkylsulfonyl or alkylsulfonyl, where R2 represents a hydroxy-substituted alkyl residue, R 2 together with the carboxylic acid residue at the o-position can form a lactone; R'g means hydrogen or methyl and. R is a hydrogen atom or an optionally substituted alkyl residue, or an R, optionally substituted phenyl residue, the residue x, ¿/ N being in the 5 or 6 position of the naphthyl nucleus. The new compounds exhibit interesting pharmacological properties, thus also anti-cancerous properties.

NO965160A 1994-06-10 1996-12-03 New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds NO965160D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9407116A FR2721021B1 (en) 1994-06-10 1994-06-10 New farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions containing them.
FR9412338A FR2725717B1 (en) 1994-10-17 1994-10-17 NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR1995/000739 WO1995034535A1 (en) 1994-06-10 1995-06-07 Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same

Publications (2)

Publication Number Publication Date
NO965160L true NO965160L (en) 1996-12-03
NO965160D0 NO965160D0 (en) 1996-12-03

Family

ID=26231226

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965160A NO965160D0 (en) 1994-06-10 1996-12-03 New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds

Country Status (15)

Country Link
EP (1) EP0764149B1 (en)
JP (1) JPH10501259A (en)
CN (1) CN1150419A (en)
AT (1) ATE175958T1 (en)
AU (1) AU2742195A (en)
BR (1) BR9508187A (en)
CA (1) CA2192389A1 (en)
CZ (1) CZ361996A3 (en)
DE (1) DE69507476D1 (en)
FI (1) FI964920A7 (en)
NO (1) NO965160D0 (en)
PL (1) PL317580A1 (en)
SK (1) SK158196A3 (en)
TW (1) TW365602B (en)
WO (1) WO1995034535A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038162A1 (en) * 1997-02-27 1998-09-03 Eisai Co., Ltd. Inhibitors of isoprenyl transferase
GB2323841A (en) * 1997-04-04 1998-10-07 Ferring Bv Group Holdings Pyridine derivatives with anti-tumor and anti-inflammatory activity
GB2323842A (en) * 1997-04-04 1998-10-07 Ferring Bv Pyridine derivatives
US6071547A (en) * 1998-10-08 2000-06-06 Superior Nutrition Corporation Textured dry mix instant nutritional drink
US6486202B1 (en) 2001-04-13 2002-11-26 Eisai Company, Limited Inhibitors of isoprenyl transferase
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
JP5489333B2 (en) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Methods of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
JP5378362B2 (en) 2007-05-21 2013-12-25 ノバルティス アーゲー CSF-1R inhibitors, compositions and methods of use
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102480966B (en) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 Fused heterocyclic compounds and uses thereof
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2013522292A (en) 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Indazole compounds and their use
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (en) 2010-08-17 2019-11-01 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
AU2012245455A1 (en) 2011-04-21 2013-10-31 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6106685B2 (en) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (en) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Novel compounds that are ERK inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
KR102196882B1 (en) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN105849099B (en) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 Polycyclic inhibitor of cyclin-dependent kinase 7 (CDK7)
ES2676734T3 (en) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Heteroatomic compounds useful for the treatment of proliferative diseases
WO2015100225A1 (en) 2013-12-27 2015-07-02 Novus International Inc. Ethoxylated surfactants
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (en) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017162122A1 (en) * 2016-03-23 2017-09-28 Yu-Jen Chen Farnesyl transferase inhibitors and uses thereof
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN112805006B (en) 2018-08-07 2024-09-24 默沙东有限责任公司 PRMT5 inhibitors
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20250152667A (en) 2023-03-02 2025-10-23 카르치문 바이오테크 게엠베하 Means and methods for diagnosing cancer and/or acute inflammatory diseases
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044333A1 (en) * 1990-06-12 1991-12-13 Jackson B. Gibbs Chemotherapeutic agents
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5504212A (en) * 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
AU2742195A (en) 1996-01-05
SK158196A3 (en) 1997-07-09
BR9508187A (en) 1997-08-12
JPH10501259A (en) 1998-02-03
FI964920A0 (en) 1996-12-09
NO965160D0 (en) 1996-12-03
EP0764149B1 (en) 1999-01-20
DE69507476D1 (en) 1999-03-04
TW365602B (en) 1999-08-01
CZ361996A3 (en) 1997-04-16
CN1150419A (en) 1997-05-21
EP0764149A1 (en) 1997-03-26
WO1995034535A1 (en) 1995-12-21
PL317580A1 (en) 1997-04-14
FI964920A7 (en) 1996-12-09
CA2192389A1 (en) 1995-12-21
ATE175958T1 (en) 1999-02-15

Similar Documents

Publication Publication Date Title
NO965160L (en) New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds
NO973608L (en) New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the compounds
NO973607L (en) New farnesyl transferase inhibitors, their preparation and preparations containing the inhibitors
HK1085A (en) 3-carbamoyl-4-hydroxy-2h-thieno-1,2-thiazine-1,1-dioxide derivatives
ES9000023A1 (en) Macrolide antibiotics and their preparation
SE8604950L (en) DEMENS IMPROVEMENT AND THERAPEUTIC AGENTS
AU7704591A (en) Novel derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present
AU1506792A (en) Surface-active agents derived from sulfosuccinic esters
AU541413B2 (en) 2-(1,4-benzodioxan-2-ylalicyl)imidazoles
ATE168691T1 (en) MACROLIDE DERIVATIVES
FI832582A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA TIENO-TIAZOLE DERIVAT OCH DESSA FOERENINGAR INNEHAOLLANDE CEILING MODEL
DK72888D0 (en) THIONOPHOSPHONIC ACID EASTERS, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES
DE3070768D1 (en) 1-((substituted-naphthyl)ethyl)-imidazole derivatives, pharmaceutical compositions containing them and methods of making them
PT88462A (en) PROCESS FOR THE PREPARATION OF MACROLIDE COMPOUNDS AND OF COMPOSITIONS CONTAINING THEM
SE8207294L (en) 1,4-THIAZANCARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE AND COMPOSITIONS OF THESE DERIVATIVES
ES337591A1 (en) Novel acrylic acid derivatives and process for the preparation thereof
ES8502700A1 (en) Derivatives of tetrahydrobenzothiazole and herbicidal compositions containing the same as an active ingredient
SE8005493L (en) 4- (HAFTALENYLOXI) PIPERIDINE DERIVATIVES
GB1041699A (en) Novel tetrahydro isoquinolinyl-methyldihydrobenzo[a]quinolizinium salts
IL57795A0 (en) Cephalosporin derivatives,their preparation and pharmaceutical compositions containing them
KR850001151A (en) Method for preparing r-alenyl-r-aminobutyric acid
ATE7921T1 (en) NEW CORTICOID 17 THIOACETALS, THEIR PRODUCTION AND USE.
YU46777B (en) PROCEDURE FOR OBTAINING NEW MACROLIDE COMPOUNDS
JPS5699473A (en) Tetrahydrothiopyrane derivative
EP0424248A3 (en) 20,21-dinoreburnamine derivatives, substituted in position 15, process for their preparation and novel intermediates so obtained, their use as medicines and compositions containing them